Vol 28, No 6 (2021)
Letter to the Editor
Published online: 2021-12-07
Heart inflammation risk after COVID-19 vaccine
123
, 3, 2, 45
, 3, 2, 45
Abstract
Not available
References
- Dzieciatkowski T, Szarpak L, Filipiak KJ, et al. COVID-19 challenge for modern medicine. Cardiol J. 2020; 27(2): 175–183.
- Wańha W, Wybraniec M, Kapłon-Cieślicka A, et al. Myocardial infarction in the shadow of COVID-19. Cardiol J. 2020; 27(5): 478–480.
- Urdaneta V, Esposito D, Mansi J, et al. Myocarditis after mRNA-1273 vaccination: a population-based analysis of 151 million vaccine recipients worldwide. MedRev. 2021.
- Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021 [Epub ahead of print].
- Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021 [Epub ahead of print].
- Boehmer TK, Kompaniyets L, Lavery AM, et al. Association between COVID-19 and myocarditis using hospital-based administrative data - united states, march 2020-january 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(35): 1228–1232.
- Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021; 385(12): 1078–1090.
- Lorente-Ros A, Monteagudo Ruiz JM, Rincón LM, et al. Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. Cardiol J. 2020; 27(5): 489–496.
- Singer ME, Taub IB, Kaelber DC. Risk of myocarditis from COVID-19 infection in people under age 20: a population-based analysis. medRxiv. 2021.
- Szarpak L, Savytskyi I, Pruc M, et al. Variant lambda of the severe acute respiratory syndrome coronavirus 2 virus: A serious threat or the beginning of further dangerous mutations. Cardiol J. 2021 [Epub ahead of print].
